Findings

What do systematic reviews say?

1,615 questions · 1,673 findings · 190 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 278 · 16.6%GRADE not reported 85 · 5.1%Very low 328 · 19.6%Low 460 · 27.5%Moderate 402 · 24%High 120 · 7.2%

Arginine butyrate plus standard care alone vs usual care

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Arginine butyrate plus standard care alone vs usual care

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Arginine butyrate plus standard care alone vs usual care

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Arginine butyrate plus standard care alone vs usual care

Adverse events · individuals with sickle cell disease and a leg ulcer

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
GRADE not reported

Propionyl‐L‐carnitine vs placebo

Complete leg ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Change in ulcer size · individuals with sickle cell disease and a leg ulcer

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low

Propionyl‐L‐carnitine vs placebo

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Adverse events ‐ not measured · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Complete closureUlcer area was determined by computerized planimetry · individuals with sickle cell disease and a leg ulcer

It is very uncertain whether RGD peptide matrix changes complete closureUlcer area was determined by computerized planimetry compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
RR 0.4 [0.15, 1.04]
1 study · 55 participants
Very low

RGD peptide matrix vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Change in size ulcers healed ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Adverse events · individuals with sickle cell disease and a leg ulcer

It is very uncertain whether RGD peptide matrix changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
RR 0.76 [0.5, 1.17]
1 study · 55 participants
Very low

Solcoseryl vs antiseptic agent

Complete leg ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found